Medicenna Therapeutics Corp. (TSX:MDNA)
Canada
· Delayed Price · Currency is CAD | Market Cap | 47.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.99M |
| Shares Out | 83.42M |
| EPS (ttm) | -0.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 116,138 |
| Average Volume | 106,418 |
| Open | 0.630 |
| Previous Close | 0.610 |
| Day's Range | 0.560 - 0.630 |
| 52-Week Range | 0.540 - 1.970 |
| Beta | 1.93 |
| RSI | 44.43 |
| Earnings Date | Jun 26, 2026 |
About Medicenna Therapeutics
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multi... [Read more]
Financial Performance
Financial StatementsNews
Medicenna Therapeutics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
MDNA11 is showing strong response rates in solid tumors, with pivotal trial planning underway. MDNA113, a novel bispecific anti-PD-1, demonstrated superior safety and efficacy in preclinical models and is set for clinical entry by year-end. MDNA55 is advancing toward phase III with a partner.
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the dev...
Medicenna Therapeutics Appoints Nageatte Ibrahim As CMO
(RTTNews) - Medicenna Therapeutics Corp. (MDNAF.PK), Thursday announced the appointment of Dr. Nageatte Ibrahim as Chief Medical Officer of the company.
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2 SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2 SK to the tumor microenviro...
Medicenna Therapeutics Announces Participation in Upcoming Conferences
TORONTO and HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the deve...
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026
Medicenna Announces Changes to Board Composition
TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the deve...
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential fo...
Medicenna Therapeutics Transcript: KOL Event
MDNA11 demonstrated strong efficacy and a favorable safety profile in refractory solid tumors, with durable responses and high disease control rates in post-checkpoint inhibitor settings. KOLs highlighted its best-in-class potential and recommended expanding key cohorts and combination studies.
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case ...
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
TORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the deve...
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the deve...
Medicenna Therapeutics Transcript: Planet MicroCap Showcase: TORONTO 2025
The conference detailed progress on a pipeline of engineered cytokine immunotherapies, highlighting strong clinical data for MDNA11 in refractory cancers and a robust outlook for upcoming data readouts. Multiple programs target large markets, with significant value inflection expected in December.
Medicenna Announces Results of Annual Meeting of Shareholders
TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the dev...
Medicenna Therapeutics Transcript: Emerging Growth Conference 2025
MDNA11 demonstrates strong response rates in hard-to-treat cancers, with pivotal data expected by year-end. The pipeline includes next-generation bispecifics and a Phase 3-ready asset, supported by solid financials and ongoing partnership efforts.
Medicenna Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Lead asset MDNA11 shows strong response rates and safety in advanced cancer trials, with key data and enrollment completion expected by year-end. The pipeline includes a novel bispecific superkine and a glioblastoma therapy that doubled survival, supported by a robust patent portfolio.
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
TORONTO and HOUSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage cancer immunotherapy company focused on ...
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our IL...
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® a...
Medicenna Therapeutics Transcript: Emerging Growth Conference 82
The conference highlighted promising clinical data for MDNA-11, with response rates of 30%-50% in hard-to-treat cancers and a strong safety profile. The pipeline includes late-stage and bispecific assets, with multiple data readouts and partnership opportunities expected in the next two quarters.
Medicenna Therapeutics Transcript: Jones Healthcare and Technology Innovation Conference 2025
MDNA11, an engineered IL-2 super agonist, is showing durable responses and favorable safety in advanced solid tumors, with key data to be presented at AACR. The pipeline includes a phase III-ready glioblastoma asset and innovative bifunctional Superkines, with strong financial runway.
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting Pre-clinical data on Medicenna's first-in-class Masked and Tumor Targeted Bifunctional anti-PD1-IL2 Superkine, MDN...
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
- Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck's (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1 t...
Medicenna Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
MDNA-11, an engineered IL-2 super agonist, is showing promising safety and efficacy in phase 1-2 trials, with robust immune activation and durable responses in checkpoint inhibitor-refractory cancers. Multiple clinical readouts and expansion into new indications are expected in 2025.
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the deve...